Grace Therapeutics GRCE
NASDAQ GRCE
$1.91 -0.06 (-2.79%)
As of: Oct 22, 2026 · 11:46 AM EDT

Grace Therapeutics (GRCE) EBITDA Margin (2020 - 2026)

Updated

Grace Therapeutics' EBITDA Margin came in at -1999.13% for fiscal Q4 2021 (quarter ended Mar 31, 2021), up 425.56 percentage points from the prior quarter.

Analysis

Grace Therapeutics (GRCE) EBITDA Margin (2020 - 2026) Analysis & Trends

For FY2021 (ended Mar 31, 2021), Grace Therapeutics' EBITDA Margin was -7905.61%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,170.58 Bn 1,139.17 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 639.26 Bn 557.79 Bn 17.26 Bn 35.95%
3 AbbVie 501.86 Bn 474.97 Bn 12.70 Bn 49.01%
4 Merck 374.72 Bn 329.10 Bn 12.21 Bn 6.02%
5 Novartis Ag 302.72 Bn 266.71 Bn 11.24 Bn -
6 Astrazeneca 268.40 Bn 242.08 Bn 12.86 Bn 33.11%
7 Amgen 242.11 Bn 197.51 Bn 7.24 Bn 46.01%
8 Gilead Sciences 193.45 Bn 167.65 Bn 6.22 Bn -124.26%
9 Pfizer 172.31 Bn 118.96 Bn 10.94 Bn 39.16%
10 Grace Therapeutics 33.07 Mn -33.19 Mn - -11,287.23%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -11,287.23%
Mar 31, 2026 -2,179.71%
Dec 31, 2025 -1,422.09%
Sep 30, 2025 -1,470.35%
Jun 30, 2025 -1,513.73%
Mar 31, 2025 -1,728.80%
Dec 31, 2024 -2,914.96%
Sep 30, 2024 -2,653.30%
Jun 30, 2024 -2,111.49%
Mar 31, 2021 -1,999.13%
Dec 31, 2020 -2,424.69%
API Access

Grace Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=GRCE&period=max&api_key=YOUR_API_KEY